Abstract 048: Impact of New Clinical Practice Guidelines on Cardiovascular Disease Risk Assessment in an Obese Pediatric Population

Hypertension ◽  
2018 ◽  
Vol 72 (Suppl_1) ◽  
Author(s):  
Edem Binka ◽  
Philip Spevak ◽  
Lauren Dibert ◽  
Tammy McLoughlin Brady
Keyword(s):  
Cardiovascular Disease ◽  
Risk Assessment ◽  
Clinical Practice ◽  
Clinical Practice Guidelines ◽  
Practice Guidelines ◽  
Disease Risk ◽  
Pediatric Population ◽  
Cardiovascular Disease Risk

scholarly journals Systematic review of international clinical guidelines for the promotion of physical activity for the primary prevention of cardiovascular diseases

2021 ◽  
Vol 22 (1) ◽  
Author(s):  
N. Aerts ◽  
D. Le Goff ◽  
M. Odorico ◽  
J. Y. Le Reste ◽  
P. Van Bogaert ◽  
...  
Keyword(s):  
Physical Activity ◽  
Cardiovascular Disease ◽  
Clinical Practice ◽  
Cardiovascular Diseases ◽  
Primary Prevention ◽  
Clinical Practice Guidelines ◽  
Practice Guidelines ◽  
Clinical Guidelines ◽  
Prevention Programs ◽  
Prevention Of Cardiovascular Disease

Abstract Background Cardiovascular diseases are the world’s leading cause of morbidity and mortality. An active lifestyle is one of the cornerstones in the primary prevention of cardiovascular disease. An initial step in guiding primary prevention programs is to refer to clinical guidelines. We aimed to systematically review clinical practice guidelines on primary prevention of cardiovascular disease and their recommendations regarding physical activity. Methods We systematically searched Trip Medical Database, PubMed and Guidelines International Network from January 2012 up to December 2020 using the following search strings: ‘cardiovascular disease’, ‘prevention’, combined with specific cardiovascular disease risk factors. The identified records were screened for relevance and content. We methodologically assessed the selected guidelines using the AGREE II tool. Recommendations were summarized using a consensus-developed extraction form. Results After screening, 27 clinical practice guidelines were included, all of which were developed in Western countries and showed consistent rigor of development. Guidelines were consistent about the benefit of regular, moderate-intensity, aerobic physical activity. However, recommendations on strategies to achieve and sustain behavior change varied. Multicomponent interventions, comprising education, counseling and self-management support, are recommended to be delivered by various providers in primary health care or community settings. Guidelines advise to embed patient-centered care and behavioral change techniques in prevention programs. Conclusions Current clinical practice guidelines recommend similar PA lifestyle advice and propose various delivery models to be considered in the design of such interventions. Guidelines identify a gap in evidence on the implementation of these recommendations into practice.

scholarly journals Utility of Nontraditional Risk Markers in Atherosclerotic Cardiovascular Disease Risk Assessment

2016 ◽  
Vol 67 (2) ◽  
pp. 139-147 ◽  
Author(s):  
Joseph Yeboah ◽  
Rebekah Young ◽  
Robyn L. McClelland ◽  
Joseph C. Delaney ◽  
Tamar S. Polonsky ◽  
...  
Keyword(s):  
Cardiovascular Disease ◽  
Risk Assessment ◽  
Disease Risk ◽  
Cardiovascular Disease Risk ◽  
Atherosclerotic Cardiovascular Disease ◽  
Risk Markers ◽  
Atherosclerotic Cardiovascular Disease Risk

scholarly journals Cardiotoxicity and cardiovascular disease risk assessment for patients receiving breast cancer treatment

2017 ◽  
Vol 3 (1) ◽  
Author(s):  
Robyn A. Clark ◽  
Tania S. Marin ◽  
Narelle M. Berry ◽  
John J. Atherton ◽  
Jonathon W. Foote ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cardiovascular Disease ◽  
Risk Assessment ◽  
Cancer Treatment ◽  
Disease Risk ◽  
Cardiovascular Disease Risk ◽  
Breast Cancer Treatment

scholarly journals Cost-Effectiveness of Drug Treatment for Chinese Patients With Stage I Hypertension According to the 2017 Hypertension Clinical Practice Guidelines

Hypertension ◽  
2020 ◽  
Vol 76 (3) ◽  
pp. 750-758
Author(s):  
Yan-Feng Zhou ◽  
Na Liu ◽  
Pei Wang ◽  
Jae Jeong Yang ◽  
Xing-Yue Song ◽  
...  
Keyword(s):  
Cardiovascular Disease ◽  
Clinical Practice ◽  
Drug Treatment ◽  
Clinical Practice Guidelines ◽  
Practice Guidelines ◽  
Cost Effective ◽  
Stage I ◽  
Chinese Patients ◽  
Lifetime Horizon ◽  
Hypertensive Patients

Systolic/diastolic blood pressure of 130 to 139/80 to 89 mm Hg has been defined as stage I hypertension by the 2017 Hypertension Clinical Practice Guidelines. Drug treatment is recommended for stage I hypertensive patients aged ≥65 years without cardiovascular disease in the 2017 Hypertension Clinical Practice Guidelines but not in the 2018 Chinese guidelines. However, the cost-effectiveness of drug treatment among this subgroup of Chinese patients is unclear. This study developed a microsimulation model to compare costs and effectiveness of drug treatment and nondrug treatment for the subgroup of stage I hypertensive patients over a lifetime horizon from a government affordability perspective. Event rates of mortality and cardiovascular complications were estimated from 3 cohorts in the Chinese population. Costs and health utilities were obtained from the national statistics report and published literature. The model predicted that drug treatment generated quality-adjusted life-years of 13.52 and associated with expected costs of $6825 in comparison with 13.81 and $7328 produced by nondrug treatment over a lifetime horizon among stage I hypertensive patients aged ≥65 years without cardiovascular disease. At a willingness-to-pay threshold of $8836/quality-adjusted life-year (the GDP per capita in 2017), drug treatment only had a 1.8% probability of being cost-effective compared with nondrug treatment after 10 000 probabilistic simulations. Sensitivity analysis of treatment costs, benefits expected from treatment, health utilities, and discount rates did not change the results. Our results suggested that drug treatment was not cost-effective compared with nondrug treatment for stage I hypertensive patients aged ≥65 years without cardiovascular disease in China.

Living Guidelines for Absolute Cardiovascular Disease Risk Assessment and Management

2019 ◽  
Vol 28 (6) ◽  
pp. 829-832 ◽  
Author(s):  
Ellie Paige ◽  
Jason Agostino ◽  
Christine Phillips ◽  
Julian Elliott ◽  
Dominique A. Cadilhac ◽  
...  
Keyword(s):  
Cardiovascular Disease ◽  
Risk Assessment ◽  
Disease Risk ◽  
Cardiovascular Disease Risk ◽  
Risk Assessment And Management
Sign in / Sign up

Export Citation Format

Share Document